References
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf (accessed December 17, 2017)
http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Praxbind/Praxbind.pdf (accessed December 17, 2017)
http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf (accessed December 17, 2017)
Simon A, Domanovits H, Ay C, Sengoelge G, Levy JH, Spiel AO (2017) The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran. J Thromb Haemost 15:1317–1321
Yip L, Deng FJ (2018) Idarucizumab dosing in kidney failure. Am J Kidney Dis 71:146
Stecher A, Vene N, Mavri A, Mijovski MB, Krevel B, Gradisek P (2017) Late rebound of dabigatran levels after idarucizumab reversal in two patients with severe renal failure. Eur J Anesthesiol 34:400–402
Chai-Adisaksopha C, Hillis C, Lim W, Boonyawat K, Moffat K, Crowther M (2015) Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review. J Thromb Haemost 13:1790–1798
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Pfrepper, C., Peschka, A., Weidhase, L. et al. Management of Dabigatran-associated bleeding in two elderly patients with acute renal failure. Ann Hematol 97, 2519–2521 (2018). https://doi.org/10.1007/s00277-018-3376-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-018-3376-8